{"id":"NCT01438411","sponsor":"Mirum Pharmaceuticals, Inc.","briefTitle":"Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis","officialTitle":"An Open Label, Single Center, Nonrandomized Continuation Study of Cholic Acid Capsules to Treat Subjects With Inborn Errors of Bile Acid Synthesis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2011-09-22","resultsPosted":"2020-08-21","lastUpdate":"2023-10-03"},"enrollment":53,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bile Acid Synthesis Defect"],"interventions":[{"type":"DRUG","name":"Cholic Acid","otherNames":["Cholic","Cholic Acid Capsules"]}],"arms":[{"label":"Cholic Acid","type":"OTHER"}],"summary":"The primary purpose of the study is to evaluate the therapeutic efficacy and safety of cholic acid in subjects with identified inborn errors of bile acid synthesis.","primaryOutcome":{"measure":"Change in Atypical Urinary Bile Acid Excretion by FAB-MS (Fast-Atom-Bombardment Ionization-Mass Spectrometry)","timeFrame":"At baseline, then every 12 months for an average of 3.5 years","effectByArm":[{"arm":"Cholic Acid","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["31899729"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":53},"commonTop":["Upper respiratory tract infection","Abdominal pain","Diarrhoea","Vitamin D decreased","Nasopharyngitis"]}}